Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer

drug protocol number
ESR-14-10649
drug sponsor
AstraZeneca
drug study
Paclitaxel
drug trial site
KFSH & RC-R
drug status
Ongoing
drug phase